A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants
← catalyst calendarSponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
63actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-16 | actual | When the study began enrolling |
| Primary completion | 2025-09-29 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-29 | actual | The whole study's end, after follow-up |
| First posted | 2025-06-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: INCB161734
- Drug: Itraconazole
- Drug: Rifampin
- Drug: Esomeprazole
- Drug: Famotidine
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetics Parameter (PK): Cmax of INCB161734
measured Up to 2 months
Pharmacokinetics Parameter: AUC(0-t) of INCB161734
measured Up to 2 months
Pharmacokinetics Parameter: AUC 0-∞ of INCB161734
measured Up to 2 months
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed